Oxycodone

Oxycodone is a semi-synthetic opioid derived from thebaine, a minor alkaloid of the opium poppy, and is used medically for moderate to severe acute or chronic pain ^[1]. Structurally it is closely related to codeine, differing by a 14-hydroxy group, a 7,8-dihydro modification, and a ketone in place of a hydroxyl. The compound was first prepared in 1916 by the German chemists Martin Freund and Edmund Speyer, entered clinical use shortly afterward, and reached the United States market in 1939.

In practice, oxycodone is given when pain is not adequately controlled by non-opioid options, and it is formulated both as immediate-release products and as controlled-release tablets designed to spread the effect across many hours ^[2]. It is metabolized mainly in the liver by the enzymes CYP3A4 and CYP2D6, the latter converting a small fraction to the more potent metabolite oxymorphone; genetic variation in these enzymes and in the opioid receptor gene can shape how individuals respond ^[2][3]. Combination products pair oxycodone with agents such as paracetamol, ibuprofen, aspirin, or the opioid antagonists naloxone and naltrexone.

Because of its strong potential for tolerance, physical dependence, and misuse, oxycodone is tightly regulated; it is a Schedule II controlled substance in the United States and holds comparable controlled status elsewhere ^[1]. The 1995 introduction of the extended-release brand OxyContin and its later widespread diversion became a central feature of the opioid crisis, prompting reformulations and stricter prescribing. Pharmacogenetic guidance has since been developed to help tailor opioid therapy according to CYP2D6 and related genotypes ^[3].

The risk that actually kills people is respiratory depression; opioids slow and shallow the breath, and a big enough dose stops it. That danger climbs steeply when oxycodone is combined with other central nervous system depressants, so mixing it with benzodiazepines, alcohol, gabapentin or pregabalin, sleep aids, muscle relaxants, or other opioids is a genuinely dangerous move and a common thread in fatal overdoses.

Everyday side effects include constipation that does not fade, nausea, vomiting, drowsiness, dizziness, itching, sweating, dry mouth, and pinpoint pupils. With regular use the body builds tolerance and physical dependence, and stopping suddenly brings a rough withdrawal; sweating, cramps, diarrhea, chills, anxiety, and insomnia that is miserable but usually not life-threatening.

Oxycodone has a high abuse liability because the euphoria is reinforcing; the original OxyContin could be crushed to defeat its time-release coating and dump a 12-hour dose at once, which drove a wave of misuse and overdose until a harder-to-crush formulation arrived in 2010. Signs of overdose are slow or stopped breathing, blue lips, pinpoint pupils, and someone you cannot wake; naloxone reverses it, so keeping it on hand is smart, and you should call emergency services immediately. Used during pregnancy it can cause neonatal opioid withdrawal. In the United States it sits in Schedule II, meaning it has an accepted medical use but a high potential for abuse and dependence.

Cannabidiol inhibits oxycodone metabolism via CYP2D6 and CYP3A4, resulting in a three-fold increase in total oxycodone exposure and a 50% increase in peak concentration; this is a pharmacokinetic interaction that extends analgesic duration acutely but accelerates tolerance development with chronic co-administration ^[4]. Diazepam and etizolam inhibit oxycodone metabolism to its active metabolite oxymorphone in in vitro studies, though clinical significance in humans differs from preclinical models ^[5]. Relatively little is documented about oxycodone interactions with non-CNS-active drugs; many potential pairings with antihypertensives, antihistamines, or gastrointestinal agents remain unstudied.

Checking a whole stack? Run it through interactions + stacks.